- Conference call and webcast to be held Monday, September 23, at 8:30am ET
NEW
HAVEN, Conn., Sept. 20,
2024 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN)
(Biohaven), today announced that it will host a conference call to
discuss topline data from Study BHV4157-206-RWE (NCT06529146), a
study designed in discussion with the US Food and Drug
Administration (FDA), to assess the effectiveness of troriluzole in
Spinocerebellar Ataxia.
Conference Call and Webcast Details
Biohaven will hold
a live conference call and webcast Monday,
September 23, 2024, at 8:30 a.m. Eastern Time. The live
event may be accessed via the Investor Relations portion of
Biohaven's website
at https://ir.biohaven.com/events-presentations/events. To
participate in the live conference call via telephone, please
register here. Upon registering, a dial-in number and unique
PIN will be provided to join the conference call.
About Troriluzole
Troriluzole is a new chemical entity
(NCE) and third-generation prodrug that modulates glutamate, the
most abundant excitatory neurotransmitter in the human body. The
primary mode of action of troriluzole is reducing synaptic levels
of glutamate. Troriluzole increases glutamate uptake from the
synapse, by augmenting the expression and function of excitatory
amino acid transporters located on glial cells that play a key role
in clearing glutamate from the synapse. Troriluzole has the
potential to be developed in a number of other diseases associated
with excessive glutamate. More information about troriluzole can be
found at the Biohaven's website:
https://www.biohaven.com/pipeline/clinical-programs/glutamate/.
About Biohaven
Biohaven is a biopharmaceutical
company focused on the discovery, development, and
commercialization of life-changing treatments in key therapeutic
areas, including immunology, neuroscience, and oncology. The
company is advancing its innovative portfolio of therapeutics,
leveraging its proven drug development experience and multiple
proprietary drug development
platforms. Biohaven's extensive clinical and preclinical
programs include Kv7 ion channel modulation for epilepsy and mood
disorders; extracellular protein degradation for immunological
diseases; TRPM3 antagonism for migraine and neuropathic pain;
TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate
modulation for OCD and SCA (spinocerebellar ataxia); myostatin
inhibition for neuromuscular and metabolic diseases, including SMA
and obesity; antibody recruiting bispecific molecules and antibody
drug conjugates for cancer. For more information, visit
www.biohaven.com.
Forward-looking Statements
This news release includes
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The use of certain words,
including "continue", "plan", "will", "believe", "may", "expect",
"anticipate" and similar expressions, is intended to identify
forward-looking statements. Investors are cautioned that any
forward-looking statements, including statements regarding the
future development, timing and potential marketing approval and
commercialization of development candidates, are not guarantees of
future performance or results and involve substantial risks and
uncertainties. Actual results, developments and events may differ
materially from those in the forward-looking statements as a result
of various factors including: the expected timing, commencement and
outcomes of Biohaven's planned and ongoing clinical
trials; the timing of planned interactions and filings with the
FDA; the timing and outcome of expected regulatory filings;
complying with applicable U.S. regulatory requirements;
the potential commercialization of Biohaven's product
candidates; the potential for Biohaven's product
candidates to be first in class therapies; and the effectiveness
and safety of Biohaven's product candidates. Additional
important factors to be considered in connection with
forward-looking statements are described
in Biohaven's filings with the Securities and
Exchange Commission, including within the sections titled "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations". The forward-looking
statements are made as of the date of this news release,
and Biohaven does not undertake any obligation to update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
Investor Contact:
Jennifer
Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
+1 (312) 961-2502
View original content to download
multimedia:https://www.prnewswire.com/news-releases/biohaven-announces-conference-call-to-discuss-topline-pivotal-study-results-in-spinocerebellar-ataxia-302254638.html
SOURCE Biohaven Ltd.